Evaluation of Lymphoma-Associated Lymphadenopathy
Begin with excisional biopsy as the definitive diagnostic approach—fine-needle aspiration is inadequate for initial lymphoma diagnosis, though core-needle biopsy may suffice when excisional biopsy is not feasible. 1
Diagnostic Approach
Tissue Acquisition (First Priority)
The Lugano Classification establishes a clear hierarchy for tissue diagnosis:
- Excisional biopsy is the gold standard, providing adequate tissue for morphology, immunohistochemistry, flow cytometry, and molecular studies 1
- Core-needle biopsy is acceptable only when excisional biopsy is not possible, or to document relapse 1
- Fine-needle aspiration alone is inadequate for initial diagnosis—if a core biopsy is nondiagnostic, proceed immediately to excisional biopsy 1, 2
This tissue-first approach is critical because lymphoma diagnosis requires comprehensive pathologic evaluation by an experienced lymphoma pathologist, and inadequate sampling leads to diagnostic delays that can negatively impact outcomes 3, 2.
Clinical Evaluation (Concurrent with Biopsy Planning)
Obtain a focused history targeting:
- Duration of lymphadenopathy (>4 weeks increases concern) 4
- Constitutional "B symptoms": fevers >101°F (38.3°C), drenching night sweats, unexplained weight loss >10% over 6 months 1
- Age >40 years, male sex, white race (malignancy risk factors) 5
- Prior malignancy, autoimmune conditions (especially rheumatologic disorders reduce lymphoma likelihood) 3
Physical examination specifics:
- Measure accessible nodal groups in centimeters 1
- Red flag locations: supraclavicular, epitrochlear, popliteal, or iliac nodes are abnormal and warrant immediate biopsy 4, 5
- Concerning characteristics: nodes >2 cm, hard consistency, matted/fused to surrounding structures 4
- Measure spleen and liver size below costal margins in midclavicular line 1
Imaging Strategy
The imaging modality depends on lymphoma FDG-avidity:
- PET-CT is the standard for FDG-avid lymphomas (most Hodgkin lymphoma, DLBCL, follicular lymphoma) for both staging and determining extent of disease 1
- CT alone for nonavid histologies (some indolent lymphomas) 1
Key staging determinations from imaging:
- Nodal involvement above/below diaphragm
- Extranodal sites (liver nodules, splenic involvement >13 cm vertical length or nodules, bone marrow) 1
- Largest tumor diameter (replaces old "bulky" designation) 1
Laboratory Testing
Essential baseline tests for prognostic indices:
- Complete blood count
- Comprehensive metabolic panel
- LDH (elevated suggests aggressive disease)
- HIV testing
- Hepatitis B and C screening
- Tests specific to prognostic scoring systems (International Prognostic Index components) 1
Critical Pitfalls to Avoid
Do NOT start corticosteroids before biopsy—they mask histologic diagnosis of lymphoma 4, 5
Do NOT rely on imaging or FNA alone—delays from inadequate initial sampling worsen outcomes 2
Do NOT order bone marrow biopsy routinely:
Younger age, smaller nodes (<3.4 cm), and prior rheumatologic conditions reduce malignancy likelihood—but do not eliminate need for tissue diagnosis if clinical suspicion persists 3
Staging After Diagnosis
Once lymphoma is confirmed histologically, use the modified Ann Arbor (Lugano) staging system 1:
- Limited disease: Stage I (one nodal group) or II (≥2 nodal groups same side of diaphragm)
- Advanced disease: Stage III (nodes both sides of diaphragm) or IV (noncontiguous extralymphatic involvement)
Note: Constitutional "B symptoms" designation only matters for Hodgkin lymphoma treatment decisions—not required for non-Hodgkin lymphomas 1
Timeline Expectations
Establishing rapid diagnostic pathways significantly improves outcomes. Studies show median time from consultation to diagnosis can be reduced to 16 days with organized rapid diagnosis clinics versus 28 days with standard approaches 3. Time from referral to first treatment should target <30 days for metastatic disease and <40 days for lymphoma 6.